- Home
- EXAS vs KNSL Comparison
EXAS vs KNSL Comparison
Compare EXAS & KNSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- KNSL
- Stock Information
- Founded
- EXAS 1995
- KNSL 2009
- Country
- EXAS United States
- KNSL United States
- Employees
- EXAS N/A
- KNSL N/A
- Industry
- EXAS Medical Specialities
- KNSL Property-Casualty Insurers
- Sector
- EXAS Health Care
- KNSL Finance
- Exchange
- EXAS Nasdaq
- KNSL Nasdaq
- Market Cap
- EXAS 10.7B
- KNSL 10.7B
- IPO Year
- EXAS N/A
- KNSL 2016
- Fundamental
- Price
- EXAS $53.02
- KNSL $475.68
- Analyst Decision
- EXAS Strong Buy
- KNSL Buy
- Analyst Count
- EXAS 20
- KNSL 10
- Target Price
- EXAS $70.68
- KNSL $491.88
- AVG Volume (30 Days)
- EXAS 2.9M
- KNSL 191.2K
- Earning Date
- EXAS 07-30-2025
- KNSL 07-24-2025
- Dividend Yield
- EXAS N/A
- KNSL 0.14%
- EPS Growth
- EXAS N/A
- KNSL 15.35
- EPS
- EXAS N/A
- KNSL 17.37
- Revenue
- EXAS $2,828,128,000.00
- KNSL $1,638,131,000.00
- Revenue This Year
- EXAS $14.58
- KNSL $12.94
- Revenue Next Year
- EXAS $12.75
- KNSL $12.99
- P/E Ratio
- EXAS N/A
- KNSL $27.42
- Revenue Growth
- EXAS 11.57
- KNSL 22.79
- 52 Week Low
- EXAS $39.97
- KNSL $366.92
- 52 Week High
- EXAS $72.83
- KNSL $531.79
- Technical
- Relative Strength Index (RSI)
- EXAS 45.95
- KNSL 55.15
- Support Level
- EXAS $51.50
- KNSL $457.38
- Resistance Level
- EXAS $53.30
- KNSL $482.81
- Average True Range (ATR)
- EXAS 1.62
- KNSL 11.31
- MACD
- EXAS -0.64
- KNSL -0.15
- Stochastic Oscillator
- EXAS 26.95
- KNSL 76.09
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.